FDA-cleared profile

VersaViewer

GE Medical Systems SCS · Radiological images; modality varies or is not specified in FDA list · FDA-cleared (510(k))

Authorized purpose: VersaViewer supports two-dimensional, three-dimensional, and four-dimensional medical-image series processing and analysis through customizable layouts, multimodality review, and measurements for trained healthcare professionals; it is not for displaying digital mammography for diagnosis.

Clinical role
Medical-image viewing, manipulation, measurement, quantification, segmentation, comparison, or reporting support.
Images and patients
Radiological images; modality varies or is not specified in FDA list · Multi-region anatomy represented in CT, MR, PET, NM, XA, and other supported studies
Key limitation
Keep in mind: Modality, study type, display, timing, mobile, diagnostic, and feature-license limits are release-specific; final decisions remain with qualified professionals.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: VersaViewer supports two-dimensional, three-dimensional, and four-dimensional medical-image series processing and analysis through customizable layouts, multimodality review, and measurements for trained healthcare professionals; it is not for displaying digital mammography for diagnosis.
  • Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Multi-region anatomy represented in CT, MR, PET, NM, XA, and other supported studies Input: Supported DICOM or other exact-submission image and study objects from the labeled modalities and workflows.
  • Who uses it?Intended users: Radiologists, physicians, technologists, and other trained healthcare professionals authorized for the labeled workflow.
  • What does the software produce?Output: Displayed image series, reformats, measurements, annotations, segmentations, comparisons, or reports for professional review.
  • What is its most important limitation?Key limitation: Modality, study type, display, timing, mobile, diagnostic, and feature-license limits are release-specific; final decisions remain with qualified professionals.

Clinical takeaway. Clinical role: VersaViewer supports two-dimensional, three-dimensional, and four-dimensional medical-image series processing and analysis through customizable layouts, multimodality review, and measurements for trained healthcare professionals; it is not for displaying digital mammography for diagnosis.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports non-clinical design control testing, including performance testing (verification, validation) and safety testing, with verification on the AW Server platform, plus engineering bench testing of the deep learning algorithm for automated segmentation of six body parts (lung, liver, bone, aorta, heart and body) on a database of retrospective CT exams, which passed the defined acceptance criteria. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
VersaViewer supports two-dimensional, three-dimensional, and four-dimensional medical-image series processing and analysis through customizable layouts, multimodality review, and measurements for trained healthcare professionals; it is not for displaying digital mammography for diagnosis.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Medical-image viewing, manipulation, measurement, quantification, segmentation, comparison, or reporting support.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Supported DICOM or other exact-submission image and study objects from the labeled modalities and workflows.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Displayed image series, reformats, measurements, annotations, segmentations, comparisons, or reports for professional review.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Healthcare institutions, radiology departments, clinics, and clinical workstations within the exact submission scope.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Radiologists, physicians, technologists, and other trained healthcare professionals authorized for the labeled workflow.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Modality, study type, display, timing, mobile, diagnostic, and feature-license limits are release-specific; final decisions remain with qualified professionals.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports non-clinical design control testing, including performance testing (verification, validation) and safety testing, with verification on the AW Server platform, plus engineering bench testing of the deep learning algorithm for automated segmentation of six body parts (lung, liver, bone, aorta, heart and body) on a database of retrospective CT exams, which passed the defined acceptance criteria. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Summary of Non-Clinical, Design Control Testing VersaViewer has successfully completed the design control testing per GE HealthCare’s quality system." … "Performance testing (Verification, Validation) x Safety Testing (Verification) The proposed VersaViewer has been successfully verified on the AW Server (K081985) platform.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports non-clinical design control testing, including performance testing (verification, validation) and safety testing, with verification on the AW Server platform, plus engineering bench testing of the deep learning algorithm for automated segmentation of six body parts (lung, liver, bone, aorta, heart and body) on a database of retrospective CT exams, which passed the defined acceptance criteria. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Summary of Non-Clinical, Design Control Testing VersaViewer has successfully completed the design control testing per GE HealthCare’s quality system." … "Performance testing (Verification, Validation) x Safety Testing (Verification) The proposed VersaViewer has been successfully verified on the AW Server (K081985) platform.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No exact submission-linked sensitivity endpoint with a verified population, threshold, tested version, and source was promoted.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No exact submission-linked specificity endpoint with a verified population, threshold, tested version, and source was promoted.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K243651 FDA evidence package for VersaViewer

  • DesignFDA 510(k) decision evidence package reviewed for exact submission identity and labeled scope
  • PopulationLabeled population and configuration described in the K243651 FDA decision material
  • Scopeexact submission
  • Tested versionVersaViewer configuration described in K243651
  • IndependenceSponsor or vendor study

K243651

Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K243651 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Supported DICOM or other exact-submission image and study objects from the labeled modalities and workflows.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K243651: VersaViewer

  2. Routing

    Source context, not route validation: The exact FDA package describes an optional One View feature whose automated workflow generates secondary capture DICOM objects and networks them to preconfigured DICOM destinations, such as PACS, for review. Interface versions and local compatibility require confirmation.

    Scope: Exact FDA submission. Packet wording: "VersaViewer also includes One View as an optional feature." … "In the subject device, a fully automated workflow generates the desired images". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-11-14 · FDA 510(k) decision material K243651: VersaViewer

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 ·

  4. Returned objects

    Source context, not route validation: Displayed image series, reformats, measurements, annotations, segmentations, comparisons, or reports for professional review.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K243651: VersaViewer

  5. Viewer/worklist/report

    Unresolved route: Displayed image series, reformats, measurements, annotations, segmentations, comparisons, or reports for professional review.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K243651: VersaViewer

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The exact FDA package describes an optional One View feature whose automated workflow generates secondary capture DICOM objects and networks them to preconfigured DICOM destinations, such as PACS, for review. Interface versions and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "VersaViewer also includes One View as an optional feature." … "In the subject device, a fully automated workflow generates the desired images". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Training
Only radiologists, physicians, technologists, and other trained healthcare professionals authorized for the labeled workflow should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K243651 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Exact public integration details remain incomplete; establish and test the supported input, output, identity, routing, archive, report, and downtime contract locally.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the exact labeled population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Modality, study type, display, timing, mobile, diagnostic, and feature-license limits are release-specific; final decisions remain with qualified professionals.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price was found in reviewed public material; productivity or value claims require local evidence.

Lifecycle monitoring

Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. No exact native-submission recall record was found in the checked snapshot; this does not exclude other product-family or later signals.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243651
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiological images; modality varies or is not specified in FDA list
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Multi-region anatomy represented in CT, MR, PET, NM, XA, and other supported studies
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-04-21
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating license or hardware basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission

    The exact FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed
  • Monitoring: Not publicly available - checked 2026-09-04 - Exact FDA submission

    The exact FDA decision and checked recall snapshot do not establish a complete local postmarket monitoring protocol. Track version, population, anatomy, protocol, input quality, edits, failures, repeats, downstream effects, downtime, incidents, recalls, and updates locally.

6 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K243651: VersaViewer

    U.S. Food and Drug Administration - Published 2025-04-21 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

Research history

  1. K243651 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K222174

RadioLens v1.0

Synapsica

Authorized purpose: RadioLens v1.0 is a medical diagnostic application for displaying, processing, storing, and transferring DICOM data other than mammography, with filtering, digital manipulation, and quantitative measurements; its optional SpindleX module analyzes potential vertebral displacement in adult cervical or lumbar spine stress X-rays and calculates measurements related to spinal-ligament injury leading to subluxation.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Spine, including cervical and lumbar vertebrae; general DICOM images excluding mammography
Decision
2023-03-28
FDA-cleared K222428

Syngo Dynamics (Version VA40F)

Siemens Medical Solutions USA, Inc.

Authorized purpose: Syngo Dynamics VA40F is a multimodality, vendor-agnostic cardiology image and information system for medical-image management and processing, with post-processing functions for image manipulation and quantification supporting interpretation and analysis for disease detection, diagnosis, and patient management within a healthcare institution's network.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Anatomy represented in multimodality cardiology medical images, excluding U.S. digital mammography diagnosis
Decision
2022-11-14
FDA-cleared K203103

Synapse 3D, Synapse 3D Base Tools v6.1

Fujifilm Corporation

Authorized purpose: Synapse 3D Base Tools is medical-imaging software that provides trained medical professionals tools to aid reading, interpreting, reporting, and treatment planning. It accepts DICOM images from imaging devices including CT, MR, CR, US, NM, PT, and XA, and provides viewing, volume rendering, multiplanar reconstruction, fusion, subtraction, segmentation, measurements, annotations, reporting, image management, and modality-specific CT and MR tools. It is not intended for primary diagnostic interpretation of mammography images.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Patient anatomy represented in supported DICOM CT, MR, CR, US, NM, PT, and XA images; mammography excluded
Decision
2021-02-09
FDA-cleared K173588

Illumeo System

Philips Medical Systems Technologies, Ltd.

Authorized purpose: Illumeo is an image-management system for trained professionals, including radiologists. It is a software package used with general-purpose computing hardware to acquire, store, distribute, process, and display images and associated data throughout a clinical environment, including digital image processing, measurement, manipulation, quantification, communication, and storage. It is not to be used for mammography.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Images and associated data represented in the clinical environment; mammography excluded
Decision
2018-01-12

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history